To investigate the short-term efficacy and safety of inebilizumab for neuromyelitis optica spectrum disorders (NMOSD).
No takes yet. Share an insight, caveat, or question.
Lou et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: